Testing a new cell therapy for recent-onset type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial is testing a one-time cell treatment (CARC-101C) for people recently diagnosed with type 1 diabetes. The goal is to see if it is safe and can help preserve the body's ability to make some insulin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 40 years old.
- You were diagnosed with type 1 diabetes 3 to 6 months ago.
- You tested positive for insulin autoantibodies (IAA) at diagnosis.
- You are currently on insulin therapy and your average blood sugar (HbA1c) is between 7% and 12%.
- Your body mass index (BMI) is between 18 and 35.
- You still make some insulin (C-peptide levels are above a certain minimum).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving your own regulatory T cells (a type of immune cell) back to you can help slow or stop the immune attack on your pancreas in type 1 diabetes. It is for people aged 8 to 65 who still make some insulin.
This trial tests a new treatment made from stem cells that may help people with diabetes who have dangerous low blood sugar episodes. It aims to see if these cells can replace some of the pancreas function and prevent severe hypoglycemia.
This trial tests a new treatment using your own immune cells (called Tregs) that are modified to target and calm the immune attack on the pancreas. It is for people diagnosed with stage 3 type 1 diabetes within the last 12 to 24 months who still make some insulin.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to stop the body's immune system from attacking insulin-producing cells in type 1 diabetes. The goal is to help preserve remaining pancreas function in people with early-stage disease.
This trial tests a new cell injection (CNK-UT009) for adults with type 1 diabetes. The goal is to see if it can help manage blood sugar and reduce insulin needs.
This trial tests a new combination treatment for children who have been diagnosed with stage 1 type 1 diabetes, meaning they have some markers but do not yet need insulin. The treatment uses special immune cells (Treg cells) and an antibody (anti-CD20) to try to preserve the body's ability to make insulin.
Hear when a new Autoimmune Type 1 Diabetes Mellitus(T1DM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.